ÌÇÐÄ´«Ã½

Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 Mg) Intravitreal Implants Vs Observation for Prevention of VA Loss Due to Radiation Retinopathy

Trial ID or NCT#

NCT05844982

Status

recruiting iconRECRUITING

Purpose

This randomized controlled trial will evaluate the effect of intravitreal faricimab or fluocinolone acetonide (FAc) intravitreal implant compared with observation on long-term visual acuity following treatment of choroidal melanoma with iodine-125 plaque brachytherapy.

Official Title

A Trial Evaluating Intravitreal Faricimab (6.0 Mg) Injections or Fluocinolone Acetonide (0.19 Mg Intravitreal Implants Vs Observation for Prevention of Visual Acuity Loss Due to Radiation Retinopathy

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: Yes
Exclusion Criteria:

Investigator(s)

Prithvi Mruthyunjaya, MD, MHS
Prithvi Mruthyunjaya, MD, MHS
Ophthalmologic oncologist, Retina specialist, Ophthalmologist
Alan Adler Professor of Ophthalmology and Professor, by courtesy, of Radiation Oncology

Contact us to find out if this trial is right for you.

Contact

Naz Jehangir